Pharma News

Researchers have discovered that the largest source of the fuel that cancer cells use to proliferate is amino acids which make up proteins, and not glucose, as earlier believed.

[adsense:336x280:8701650588]

As the news about Russian tennis ace Maria Sharapova admitting to take a banned drug meldonium which led to her failing a drug test at the Australian Open in January shook the world, health experts say that the drug commonly given to heart patients can increase oxygen uptake and endurance levels in healthy people.

In a development that could lead to new treatment for those who have suffered failed pregnancies, researchers have discovered that a lack of stem cells in the womb lining causes thousands of women to suffer from recurrent miscarriages.

A new breed of mosquitoes laden with bacteria has proven capable of controlling the spread of dengue fever and the Zika virus, said Vietnam's health officials on Monday.

A diet rich in a fatty acid that is essential for nutrition and found in grapeseed and other oils but not in olive oil may lower the risk of heart disease and diabetes, suggests a study.

Researchers have found that a blood test may be able to sound early warning bells that patients with advanced melanoma skin cancer are suffering from relapse.

Obesity and eating fatty food are significant risk factors for many types of cancer. A new study has revealed that a high-fat diet makes the cells of the intestinal lining in the gut more likely to become cancerous.

Common asthma symptoms are associated with increased levels of stress and anxiety in teens, a study has found.A study by Henry Ford Hospital in Detroit city of Michigan state in the US has found in a small study of 38 asthma patients aged 14-17, that their average scores for stress and anxiety levels were higher than those seen in the general population.

Consuming foods and beverages with a high glycemic index, such as white bread or bagels, corn flakes and puffed rice, is linked with an increased risk of developing lung cancer, says a study.

Baxalta Incorporated announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ADYNOVI, an extended circulating half-life recombinant Factor VIII (rFVIII) treatment, for pediatric, adolescent and adult patients with hemophilia A and for use during surgery. Currently licensed in the U.S. as ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] and under regulatory review in Japan, Canada and Switzerland, ADYNOVI is the only rFVIII treatment for hemophilia A developed based on the demonstrated efficacy of ADVATE [Antihemophilic Factor (Recombinant)].